Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory. The Company's novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Natera's statistical algorithms combine these measurements with data available from the broader scientific community to detect a wide range of serious conditions with best-in-class accuracy and coverage. The Company's goal is to develop and commercialize non- or minimally-invasive tests to determine the likelihood of a wide range of genetic conditions. Natera's tests are used for the detection of genetic variations covering a broad set of diseases, such as Down syndrome, which can enable diagnosis and treatment.

Company Growth (employees)
San Carlos, US
Size (employees)
852 (est)
Natera was founded in 2004 and is headquartered in San Carlos, US

Key People/Management at Natera

Matthew Rabinowitz

Matthew Rabinowitz

Jonathan Sheena

Jonathan Sheena


Natera Office Locations

Natera has offices in San Carlos, New York, Raleigh, Austin and in 20 other locations
San Carlos, US (HQ)
410 201 Industrial Rd
Show all (24)

Natera Financials and Metrics

Natera Financials

Natera's revenue was reported to be $217.1 m in FY, 2016

Revenue (Q3, 2017)

56.7 m

Net income (Q3, 2017)

(27.1 m)

EBIT (Q3, 2017)

(25 m)

Market capitalization (22-Dec-2017)

507.7 m

Cash (30-Sep-2017)

11.2 m
Natera's current market capitalization is $507.7 m.
USDFY, 2015FY, 2016


190.4 m217.1 m

Revenue growth, %


R&D expense

27.7 m41.9 m

General and administrative expense

109.6 m136.1 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


45.1 m44.9 m61.9 m52 m53.9 m46.9 m53.6 m56.7 m

R&D expense

8.8 m10.3 m11.3 m12.7 m11.8 m

General and administrative expense

28.1 m27.9 m30.4 m33.2 m34.9 m37.6 m34.3 m

Operating expense total

28.1 m27.9 m39.2 m43.5 m46.3 m50.2 m46.1 m
USDFY, 2015FY, 2016


28.9 m15.3 m

Accounts Receivable

154.8 m218.6 m


5.3 m7.1 m

Current Assets

250.7 m174.1 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


62.2 m196.2 m34 m16.6 m25.3 m9.1 m7.1 m11.2 m


14.6 m12.7 m6.7 m8.9 m9.2 m8.2 m7.4 m6.4 m

Current Assets

85.8 m246.3 m248.6 m237.2 m212.3 m140.2 m123.1 m169.2 m


15 m14 m15.1 m19.1 m25.6 m31.8 m31.3 m
    USDFY, 2015FY, 2016

    Net Income

    (70.3 m)(95.8 m)

    Depreciation and Amortization

    5.5 m6.2 m

    Accounts Receivable

    (450 k)(8.5 m)


    (3.8 m)(2.1 m)
    USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (19.7 m)(17.6 m)(8.7 m)(23.2 m)(26 m)(36 m)(27.1 m)


    14.6 m12.7 m6.7 m8.9 m9.2 m8.2 m6.4 m

    Accounts Payable

    8.9 m6.1 m9 m9.2 m8.8 m6.6 m3.8 m
      USDY, 2017


      66.5 k

      Financial Leverage

      6.8 x
      Show all financial metrics

      Natera Market Value History

      Natera Median Salaries

      Source: 43 public H-1B filings from Natera

      Natera's Web-traffic and Trends

      Natera Online and Social Media Presence

      Natera News and Updates

      Liquid Biopsy Market: Industry Latest Trends & Global Outlook 2016-2024

      Main factors fueling the demand for diagnostics using liquid biopsy are growing incidences of lung cancer, gastrointestinal cancer, and breast cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Noninvasive Prenatal Testing Market Size to Expand at 10.2% CAGR by 2024

      At present, Persistence Market Research values the global noninvasive prenatal testing market at just over US$ 665 Mn, and expects the market to incur revenue growth at an impressive 10.2% CAGR. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Natera Company Life and Culture

      You may also be interested in